AVIEW LCS vs qXR-CTR
AI Verdict
Choose AVIEW LCS if…
Choose AVIEW LCS if your institution requires a comprehensive, AI-powered solution for multi-faceted cardiopulmonary assessment from low-dose CT scans. This tool is ideal for lung cancer screening programs that need automated nodule detection, detailed quantification, Lung-RADS classification, and integrated assessment of emphysema and coronary artery calcification for a holistic patient risk profile.
View AVIEW LCS →Choose qXR-CTR if…
Choose qXR-CTR if your primary need is a rapid, AI-driven assessment of heart size and potential heart failure risk directly from standard chest X-ray images. This solution is best suited for high-volume screening environments or emergency departments where quick, initial cardiac insights are crucial using an easily accessible imaging modality.
View qXR-CTR →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AVIEW LCS | qXR-CTR |
|---|---|---|
| Pricing | Subscription or one-off payment | Unknown |
| Deployment | Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker) | Can be deployed on cloud or on-premise. The Qure.ai app receives DICOM studies via DICOM network protocol from medical systems (PACS/Modality) or can import DICOM from the local system. The received DICOM study is processed in Qure's cloud server, and AI-processed reports are displayed on the app. |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AVIEW LCSAVIEW LCS offers a comprehensive, integrated workflow for multiple analyses (lung nodules, COPD, CAC) from a single CT scan, including automated reporting and PACS/RIS integration. This broad feature set, designed to streamline complex radiology workflows, suggests higher overall usability for a wider range of diagnostic needs. While qXR-CTR is simpler for a single, specific task on X-rays, AVIEW LCS's multi-faceted approach provides greater efficiency for radiologists dealing with CT interpretations.
Clinical Value
AVIEW LCSAVIEW LCS provides a multi-faceted assessment from a single CT scan, covering critical areas such as lung cancer screening, COPD, and coronary artery calcification with detailed quantification. This addresses multiple significant health concerns with high-resolution imaging, offering a broader and deeper range of clinical insights. In contrast, qXR-CTR focuses on a single measurement (CTR) from chest X-rays, which, while valuable, has a more limited diagnostic scope.
Pricing & Value
AVIEW LCSBoth tools require direct contact for pricing, making a direct cost comparison impossible. However, AVIEW LCS offers a significantly broader range of diagnostic capabilities, including multiple disease assessments (oncology, pulmonology, cardiology) from a single CT scan. This comprehensive functionality suggests a higher potential for overall value, as it can consolidate several analyses and potentially streamline more aspects of clinical workflow compared to a single-purpose tool.
Enterprise Readiness
AVIEW LCSBoth tools offer flexible deployment options (cloud, on-premise, hybrid) and possess essential compliance certifications (HIPAA, FDA clearance, BAA). However, AVIEW LCS explicitly highlights its 'Integration with PACS/RIS and third-party platforms,' which is a critical aspect for seamless enterprise adoption and workflow integration. While qXR-CTR likely has integration capabilities, AVIEW LCS's explicit mention and broader feature set imply a more robust and proven enterprise integration strategy.
Innovation
AVIEW LCSAVIEW LCS demonstrates a higher degree of innovation by integrating multiple complex AI analyses (lung nodules, COPD, CAC) from a single low-dose CT scan, including advanced quantification and automated follow-up comparisons. This multi-parametric, integrated approach for a high-resolution modality represents a more significant leap in diagnostic capability. qXR-CTR, while useful, primarily automates a single, established measurement (CTR) from chest X-rays, which is less innovative in its scope.
Support & Docs
TieThe provided structured facts do not contain any specific information regarding the availability or quality of support and documentation for either AVIEW LCS or qXR-CTR. Without additional verifiable details from external sources, it is not possible to differentiate between the two tools on this dimension. Therefore, the assessment for support and documentation results in a tie.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AVIEW LCS | qXR-CTR |
|---|---|---|
| Tool Name | AVIEW LCS | qXR-CTR |
| Company | Coreline Soft Co. | Qure.ai Technologies |
| Primary Focus | AI-powered solution for the detection and analysis of lung nodules, lung cancer, COPD, and coronary artery calcification from a single low-dose CT scan. | AI-powered software that automates the measurement of the cardiothoracic ratio (CTR) from chest X-ray images, aiding in the assessment of heart size and potential heart failure risk. |
| Key AI Capabilities | Automated lung nodule detection and analysis, Lung-RADS classification and reporting, Nodule volume quantification and 3D segmentation, Emphysema quantification (LAA index), Coronary Artery Calcification (CAC) scoring (Agatston, volume, mass), Automated comparison of nodules in follow-up CT scans, Comprehensive, automated report generation. | Automates the measurement of the cardiothoracic ratio (CTR). |
| Target Specialties | Cardiology, Oncology, Pulmonology, Radiology | Cardiology, Radiology |
Videos
Demos, reviews, and walkthroughs featuring AVIEW LCS and qXR-CTR.